Astellas Drops Alzheimer’s Compound After Phase II Interim Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm will discontinue FK962 after data did not indicate clear efficacy for the treatment of Alzheimer’s disease.
You may also be interested in...
Seroquel SR NDA Submitted For Schizophrenia
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.